SavedAdd your journal

Journals / Marmara Pharmaceutical Journal / 2018 / Cilt: 22 - Sayı: 4

Comparison of intestinal permeability of nebivolol hydrochloride loaded solid lipid nanoparticles with commercial nebivolol tablet

Evren Homan GÖKÇE
Mustafa Sinan KAYNAK
Aysu YURDASİPER
Neslihan ÜSTÜNDAĞ-OKUR
Pages
578–586
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PEG modified SLN can be used to enhance oral absorption of NBV, and SLNs alone can be used as permeation enhancer in oral drug delivery..

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The oral application of drugs is the most popular route for achieving systemic effects, nevertheless, it is limited by difficulties related to physicochemical properties of the drug.
📊
Key Findings & Data:Solid lipid nanoparticles (SLNs) are appealing extensive notice because of showing increased solubility and improved oral bioavailability via different mechanisms.
💡
Conclusion & Impact:PEG modified SLN can be used to enhance oral absorption of NBV, and SLNs alone can be used as permeation enhancer in oral drug delivery..
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The oral application of drugs is the most popular route for achieving systemic effects, nevertheless, it is limited by difficulties related to physicochemical properties of the drug. Solid lipid nanoparticles (SLNs) are appealing extensive notice because of showing increased solubility and improved oral bioavailability via different mechanisms. The aim of the study is to compare and peruse the in-situ permeation of nebivolol (NBV) loaded SLN and its commercial tablet formulation used for the treatment of hypertension. For this aim Single-Pass Intestinal Perfusion (SPIP) method was used for in-situ permeation studies. NBV loaded SLNs were prepared and modified with polyethylene glycol (PEG). In order to prepare SLNs by homogenization technique, compritol, lecithin and poloxamer were chosen. Particle sizes of blank and loaded SLN were 213.4±17.5 and 264.1±18.8 nm, respectively with polydispersity index values of approximately 0.3 for each. NBV loading resulted in positive electrical charge on SLNs. The encapsulation efficiency was 98.04±0.2 %. Permeability coefficient values were tripled when NBV was incorporated in SLNs and doubled when pure NBV was given separately with a blank SLN. PEG modified SLN can be used to enhance oral absorption of NBV, and SLNs alone can be used as permeation enhancer in oral drug delivery..

🔖

Cite This Article

GÖKÇE, E. H., KAYNAK, M. S., YURDASİPER, A., ÜSTÜNDAĞ-OKUR, N. (2018). Comparison of intestinal permeability of nebivolol hydrochloride loaded solid lipid nanoparticles with commercial nebivolol tablet. Marmara Pharmaceutical Journal, Cilt: 22 - Sayı: 4, 578–586. https://ajindex.com/articles/283622

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Campbell N, Young ER, Drouin D, Legowski B, Adams MA, Farrell J, Kaczorowski J, Lewanczuk R, Lum-Kwong MM, Tobe S. A framework for discussion on how to improve prevention, management, and control of hypertension in Canada. Can J Cardiol. 2012; 28(3): 262–269
  2. Ahada A, Aqil M, Kohli K, Sultana Y, Mujeeb M. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: Statistical optimization, characterization and pharmacokinetic assessment. Int J Pharm. 2013; 443(1–2): 26–38
  3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohem M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM. ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281–1357
  4. Altoama K, Yassine Mallem M, Thorin C, Betti E, Desfontis J. Effect of nebivolol treatment during pregnancy on the genital circulation, fetal growth and postnatal development in the Wistar rat. Eur J Pharm. 2015; 758: 31–39
  5. Wang S, Chow M, Zuo Z. An approach for rapid development of nasal delivery of analgesics—Identification of relevant features, in vitro screening and in vivo verification. Int J Pharm. 2011; 420(1): 43–50
  6. Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer. 2008; 44(3): 334–340
  7. Das S, Chaudhary A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011; 12(1): 62-76
  8. Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces. 2014; 116: 81–87
  9. Dery AS, Hamilton LA, Starr JA. Nebivolol for the treatment of heart failure disclosures. Am J Health Syst Pharm. 2011; 68(10): 879-886
  10. Veverka A, Nuzum DS, Jolly JL. Nebivolol: A thirdgeneration β-adrenergic blocker. Ann Pharmacother. 2006; 40(7- 8): 1353-1360
  11. Lennernas H. Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv Drug Deliv Rev. 2007; 59(11): 1